Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | WDR5 | P61964 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556648 | 1.00 | ALDH1A1 (0.62) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL7795268 | 0.88 | ALDH1A1 (0.58) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL30310769 | 0.88 | ALDH1A1 (0.53) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL30310802 | 0.87 | ALDH1A1 (0.50) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL15508779 | 0.86 | GAA (0.67) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL14707194 | 0.84 | GAA (0.69) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL1026206 | 0.84 | GAA (0.47) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL3313887 | 0.83 | GAA (0.72) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL30464734 | 0.83 | ALDH1A1 (0.66) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL2461666 | 0.83 | ALDH1A1 (0.66) | ALDH1A1LMNAKMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| CN-115197221-B | Dihydropyrazolopyrimidinone macrocyclic derivatives and their use | 轩竹(北京)医药科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-20230075765-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE TARGETING EGFR MUTATION, AS WELL AS THE PREPARATIVE METHOD AND THE USE THEREOF | CHENGDU WEST CHINA PRECISION MEDICINE INDUSTRY TECHNOLOGY RESEARCH INSTITUTE CO., LTD (CN) | 2023-03-09 | — | — | US | disclosed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-115197221-A | Dihydropyrazolopyrimidinone macrocyclic derivatives and application thereof | 轩竹生物科技股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-111848631-B | Pyrrolo [2,3-d ] pyrimidine derivative targeting EGFR mutation and preparation method and application thereof | 四川大学华西医院 | 2022-04-19 | — | — | CN | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-111848631-A | Pyrrolo [2,3-d ] pyrimidine derivative targeting EGFR mutation and preparation method and application thereof | 四川大学华西医院 | 2020-10-30 | — | — | CN | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140031351-A1 | Macrocyclic Compounds as ALK, FAK and JAK2 Inhibitors | CEPHALON, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2686323-A1 | MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012125603-A1 | MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2004046118-A2 | 2-4-(DI-PHENYL-AMINO)-PYRIMIDINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALDH1A1 2511/4885LMNA 4393/4885KMT2A 382/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | ALDH1A1 999/4885LMNA 1830/4885KMT2A 3265/4885 |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | ALDH1A1 2764/4885LMNA 3229/4885KMT2A 961/4885 |
| US-20230075765-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE TARGETING EGFR MUTATION, AS WELL AS THE PREPARATIVE METHOD AND THE USE THEREOF | EGFR, ERBB2, PTPN7 | ALDH1A1 2967/4885LMNA 4834/4885KMT2A 2754/4885 |
| US-20140031351-A1 | Macrocyclic Compounds as ALK, FAK and JAK2 Inhibitors | JAK2, ALK, JAK1 | ALDH1A1 1755/4885LMNA 2984/4885KMT2A 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.